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Purpose: To assess the safety and efficacy of transitioning patients whose intraocular pres-
sure (IOP) had been insufficiently controlled on prostaglandin analog (PGA) monotherapy to 
treatment with travoprost 0.004%/timolol 0.5% fixed combination with benzalkonium chloride 
(TTFC).
Methods: This prospective, multicenter, open-label, historical controlled, single-arm study 
transitioned patients who had primary open-angle glaucoma, pigment dispersion glaucoma, or 
ocular hypertension and who required further IOP reduction from PGA monotherapy to once-
daily treatment with TTFC for 12 weeks. IOP and safety (adverse events, corrected distance 
visual acuity, and slit-lamp biomicroscopy) were assessed at baseline, week 4, and week 12. 
A solicited ocular symptom survey was administered at baseline and at week 12. Patients and 
investigators reported their medication preference at week 12.
Results: Of 65 patients enrolled, 43 had received prior travoprost therapy and 22 had received 
prior nontravoprost therapy (n = 18, bimatoprost; n = 4, latanoprost). In the total population, 
mean IOP was significantly reduced from baseline (P = 0.000009), showing a 16.8% reduction 
after 12 weeks of TTFC therapy. In the study subgroups, mean IOP was significantly reduced 
from baseline to week 12 (P = 0.0001) in the prior travoprost cohort (19.0% reduction) and in 
the prior nontravoprost cohort (13.1% reduction). Seven mild, ocular, treatment-related adverse 
events were reported. Of the ten ocular symptom questions, eight had numerically lower per-
centages with TTFC compared with prior PGA monotherapy and two had numerically higher 
percentages with TTFC (dry eye symptoms and ocular stinging/burning). At week 12, TTFC 
was preferred over prior therapy for 84.2% of patients (48 of 57) by the patients themselves, 
and for 94.7% of patients (54 of 57) by their physicians.
Conclusion: When TTFC replaced PGA monotherapy in patients whose IOP had been uncon-
trolled, the outcome was a significant reduction in IOP and an acceptable safety and tolerability 
profile. Most patients and investigators preferred TTFC to prior PGA monotherapy.
Keywords: fixed combination, glaucoma, intraocular pressure, prostaglandin analog, timolol, 
travoprost
Introduction
Travoprost 0.004%/timolol maleate 0.5% fixed combination with benzalkonium 
  chloride (TTFC) gained its first commercial approval as DuoTrav (Alcon   Laboratories, 
Inc, Fort Worth, TX) eye drops in 2006 for the treatment of patients with open-angle 
glaucoma or ocular hypertension who need further reduction of intraocular pres-
sure (IOP) from a beta-blocker or a prostaglandin analog (PGA) monotherapy.1 
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Compared with concomitant therapy, fixed-combination 
products are advantageous because of increased convenience 
to the patient (due to dispensing from only one bottle), avoid-
ance of drug washout (as may occur when two individual 
drugs are administered too quickly in succession), and 
reduced lifetime exposure to ocular preservatives.
TTFC is composed of a PGA and a beta-blocker, the two 
drugs that are most often used as first-line therapy for ocular 
hypertension or glaucoma.2 The combination of these two 
agents is commonly used to treat patients whose IOP has 
failed to demonstrate sufficient reduction on monotherapy. 
Randomized studies have demonstrated that TTFC produces 
a significant reduction in IOP compared with single-agent 
timolol or travoprost.3–5
The current study examines replacement therapy for 
patients receiving insufficient IOP control from PGA mono-
therapy and incorporates two important elements into its 
design: evening dosing and transition from monotherapy. The 
dosing timing is important because the first PGA-based fixed-
combination product available, latanoprost 0.005%–timolol 
maleate 0.5% fixed combination (Xalacom®; Pfizer, Inc, 
New York, NY), was approved for once-daily morning dos-
ing. Thus, despite the fact that TTFC was approved without 
a specified timing for its once-daily dosing,1 several studies 
have used morning dosing to examine its efficacy.5–7   However, 
outcomes of studies investigating the preferred timing of 
TTFC dosing have been mixed, with one study showing an 
efficacy advantage for evening dosing8 and two reporting no 
difference between morning and evening dosing.9,10 Clearly, 
additional investigation of the TTFC dosing schedule is 
  warranted. The transition design of the current study, in which 
medication was changed from PGA monotherapy to TTFC, 
is desired because it mimics what is often done in routine 
clinical practice, unlike the randomized studies that have 
been conducted to compare TTFC to other therapies under 
artificially controlled conditions.3–5,11–13 The aim of the current 
study was to assess the safety and efficacy of once-daily TTFC 
dosed in the evening in patients with open-angle glaucoma 
or ocular hypertension who had received insufficient IOP 
reduction with PGA monotherapy.
Methods
Study design
This was a prospective, multicenter, open-label, historical 
controlled, single-arm, 12-week transition study in patients 
who had primary open-angle glaucoma, pigment dispersion 
glaucoma, or ocular hypertension, and who required further 
IOP reduction despite treatment with PGA monotherapy. 
At the screening/baseline visit, which was scheduled at   
10 am, all patients who enrolled in the study completed the 
ocular symptom survey, discontinued their PGA monotherapy, 
and were given travoprost 0.004%/timolol 0.5% fixed combi-
nation (DuoTrav® eye drops; Alcon Laboratories, Inc), along 
with instructions to self-administer the topical ocular medica-
tion one drop once daily at 8 pm for 12 weeks. Patients were 
required to return at week 4 and week 12 (within 1 hour of 
the time of IOP assessment at the screening/baseline visit) for 
IOP and safety assessments in both eyes. At week 12, patients 
completed the ocular symptom survey, and both patients and 
investigators completed the global preference survey. The 
protocol was approved by all relevant Institutional Review 
Boards and the study was performed in compliance with the 
ethical principles of the Declaration of Helsinki and Good 
Clinical Practice. All participating patients provided written 
informed consent.
Participants
Patients from four sites in Brazil were recruited by inves-
tigators to participate in this study. Eligible patients were 
adults ($18 years of age) with a clinical diagnosis of pri-
mary open-angle glaucoma, pigment dispersion glaucoma, 
or ocular hypertension in at least one eye [study eye(s)]. 
IOP, measured at 10 am, had to be between 19 mmHg and 
25 mmHg in the study eye(s) and #35 mmHg in both eyes 
after having been treated with PGA monotherapy for at least 
2 weeks prior to the screening/baseline visit. If both eyes 
were eligible for the study, both eyes were treated with study 
medication, but only the right eye was chosen for analysis. 
The last dose of PGA must have been instilled correctly 
the night prior to the screening/baseline visit. IOP had to 
be considered safe in both eyes, such that clinical stability 
of vision and the optic nerve was assured throughout the 
trial. Moreover, in nonstudy eyes, IOP had to be controlled 
without pharmacologic therapy or on the study medication 
alone. In addition, patients were required to have a corrected 
distance visual acuity (CDVA) of 20/200 or better in each 
eye and those with glaucoma had to have a recent (within 
3 months) visual field examination showing a mean deviation 
better than –15 dB and be without threat to fixation. Finally, 
eligible patients had to be able to follow instructions, to be 
willing and able to attend all study visits, and to provide 
informed consent prior to screening.
Patients were excluded if they met any of the following 
criteria: any abnormality preventing reliable applanation 
tonometry in either eye; any opacity or patient uncoopera-
tiveness that restricted adequate examination of the anterior 
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chamber of the study eye(s); risk of visual field or visual 
acuity worsening as a consequence of participation in the 
trial, in the investigator’s opinion; intraocular conventional 
surgery or laser surgery in the study eye(s) less than 3 months 
prior to the screening/baseline visit; progressive retinal or 
optic nerve disease from any cause; corneal dystrophies in 
either eye; concurrent infectious/noninfectious conjunctivitis, 
keratitis, or uveitis in either eye; history of ocular herpes 
simplex; history or risk of uveitis or cystoid macular edema; 
severe allergic rhinitis; unwillingness to accept the risk of 
darkened irides or eyelash changes; known medical history of 
allergy, hypersensitivity, or poor tolerance to any components 
of the study medication that was deemed to be clinically 
significant, in the investigator’s opinion; use of topical or 
systemic beta-adrenergic blockers or topical or systemic 
steroids; bronchial asthma or history of bronchial asthma, 
bronchial hyperreactivity, or severe chronic obstructive pul-
monary disease that would preclude the safe administration 
of a topical beta-blocker; sinus bradycardia, second-degree 
or third-degree atrioventricular block, sinoatrial block, overt 
cardiac failure, or cardiogenic shock that would preclude the 
safe administration of a topical beta-blocker; use of systemic 
medications known to affect IOP, which had not been on a 
stable course for 7 days prior to the screening/baseline visit or 
which had an anticipated dosing change during the course of 
the study; any clinically significant, serious, or severe medical 
or psychiatric condition; any condition that, in the investi-
gator’s opinion, would interfere with optimal participation 
in the study or present a special risk to the patient; participa-
tion in any other investigational study within 30 days prior 
to the screening/baseline visit; women who were pregnant 
or lactating; and women of childbearing potential who were 
not using reliable means of birth control.
Outcomes
Efficacy parameters were IOP evaluations, which were per-
formed at each visit using a Goldmann applanation tonometer 
that had been calibrated within the month prior to the screen-
ing/baseline visit. Week 4 and week 12 visits were scheduled 
within 1 hour of the time of the patient’s screening/baseline 
visit (ie, 10 am ± 1 hour). The primary efficacy outcome was 
the change in mean IOP from baseline in patients who transi-
tioned from prior travoprost therapy to TTFC. For secondary 
efficacy outcomes, the same outcome was measured in the 
total patient population and in patients who had received prior 
nontravoprost PGA monotherapy (bimatoprost or latano-
prost). Exploratory efficacy parameters assessed were the 
percentage of patients   reaching target IOP (#18 mmHg) and 
the percentage of patients achieving $2 mmHg reductions 
in IOP from baseline.
Safety variables included solicited adverse events (AEs, 
via a solicited ocular symptom survey), unsolicited AEs, 
CDVA, and slit-lamp biomicroscopy. The solicited ocular 
symptom survey, which was completed by each patient at the 
screening/baseline visit and at the week 12 visit, contained 
eleven questions: ten about the occurrence of individual 
ocular symptoms (dry eye, photophobia, increased tearing, 
stinging/burning, crusting, itching, foreign body sensation, 
irritation, and redness [as judged by the patient and by 
others]), and one about the ease of instillation of the study 
medication. This survey is not a validated instrument, but 
it has been used in a clinical trial published previously14 to 
assess patient experience with other types of IOP-lowering 
therapies. Adverse events were collected, monitored, and 
evaluated throughout the study and were recorded at each 
visit. CDVA was measured in the study eye at each visit 
using a Snellen visual acuity chart. If patients had more 
than one error on a line, CDVA values were rounded up to 
the poorer line. Slit-lamp biomicroscopy was performed at 
each visit using the investigator’s usual clinical technique. 
Tolerability was assessed at the week 12 visit via a global 
preference survey, which involved asking both patients and 
investigators to choose which therapy they preferred: TTFC 
or previous PGA monotherapy.
Objectives
The primary objective of this study was to assess the safety 
and efficacy of TTFC as transition therapy for patients with 
primary open-angle glaucoma, pigment dispersion glaucoma, 
or ocular hypertension who had not achieved sufficient 
reduction in IOP on PGA monotherapy. We hypothesized 
that, on average, patients switched from any prior PGA 
monotherapy to TTFC would demonstrate further reductions 
in IOP while experiencing sufficient tolerability with their 
new medication.
Statistical methods
Mean change in IOP between prior therapy (at screening/
baseline) and TTFC (at week 4 and week 12) was   compared 
using a one-way analysis of variance (ANOVA) test.   Assuming 
a standard deviation (SD) of 2.8 mmHg and an α-level of 0.05, 
this study provided an 80% power to detect a difference of 
1.5 mmHg between travoprost and TTFC if at least 27 patients 
were analyzed for that cohort (prespecified   calculation) or a 
90% power to detect a difference of 1.5 mmHg if at least 39 
patients were analyzed (post hoc calculation). The percentage 
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of patients who preferred TTFC compared with those who 
preferred prior therapy or who judged the two treatments to 
be similar was analyzed using a chi-square test, as was the 
percentage of investigators who preferred TTFC. Mean age 
of the two patient cohorts was compared using an unpaired 
Student’s t-test and both sex and race were compared using a 
chi-squared test.
An α-level of 0.05 was used to declare statistical 
  significance. All data analyses, which were intent-to-treat 
(ITT), were two-sided. For patients in the ITT analysis who 
attended at least one visit but were missing one or more other 
visits, the last observation was carried forward. If both eyes 
were   eligible for analysis, the right eye was used. Statistical 
analysis was performed using Statistica 5.1 (StatSoft Inc, 
São Caetano do Sul, São Paulo, Brazil) by a biostatistician 
who had been contracted by the study sponsor.
Results
Participants
A total of 65 patients were enrolled and treated with TTFC 
from June 4, 2009 through November 26, 2010. All 65 
patients were included in the ITT population. Two patients 
in the ITT population who completed the study had an IOP 
less than 19 mmHg at the screening/baseline visit in the study 
eye, which violated the inclusion criterion stating that patients 
must have had an IOP between 19 mmHg and 25 mmHg in 
the study eye. One patient who had received prior travoprost 
(for at least 2 weeks) was lost to follow-up before the week 4 
visit. Seven additional patients discontinued the study by the 
week 12 visit (n = 4, lack of response to study medication; 
n = 1, adverse event; n = 2, lost to follow-up). Therefore, 57 
patients completed the study.
Demographics and baseline 
characteristics
Demographics and baseline characteristics of the ITT popu-
lation are shown in Table 1. The patient population had a 
mean age of 61.7 years. Forty-three patients had received 
prior travoprost therapy and 22 had received prior   treatment 
with either bimatoprost (n = 18) or latanoprost (n = 4). 
No   statistical differences were observed in any of the demo-
graphics between patients receiving prior travoprost and 
patients receiving prior nontravoprost therapy.
Intraocular pressure
The primary endpoint of the study, mean change in IOP 
from travoprost to TTFC, demonstrated a significant 18.5% 
reduction after 4 weeks of TTFC (20.5 ± 2.1 mmHg versus 
16.7 ± 3.2 mmHg; P = 0.0001) and a significant 19.0% 
reduction after 12 weeks of TTFC (20.5 ± 2.1 mmHg 
  versus 16.6 ± 3.0 mmHg; P = 0.0001; Figure 1). A similar, 
significant decrease in mean IOP was observed whether 
  examining  the  total  ITT  population  at  week  4 
(20.8 ± 2.0 mmHg versus 17.3 ± 2.9 mmHg; P = 0.00002; 
16.8%) or week 12 (20.8 ±  2.0  mmHg  versus 
17.3 ± 3.2 mmHg; P = 0.000009; 16.8%) or the cohort 
of patients receiving prior nontravoprost therapy at 
week 4 (21.3 ± 1.8 mmHg versus 18.2 ± 2.0 mmHg; 
P = 0.0001; 14.6%) or week 12 (21.3 ± 1.8 mmHg versus 
18.5 ± 3.1 mmHg; P = 0.0001; 13.1%).
Table 1 Patient demographics and baseline characteristics
Demographic/ 
baseline characteristic
Total population 
N = 65
Prior therapy P value 
(travoprost vs 
nontravoprost)
Travoprost 
N = 43
Nontravoprost 
N = 22
Age, years
  Mean ± standard deviation 61.7 ± 10.3 61.4 ± 11.3 62.3 ± 8.3 0.77
  Median 61 60 61.5  
  Minimum–maximum 30–85 30–82 49–85  
Race, n (%)
  White 41 (63.1%) 25 (58.1%) 16 (72.7%) 0.38*
  Mixed-race 15 (23.1%) 12 (27.9%) 3 (13.6%)
  Black 9 (13.8%) 6 (14.0%) 3 (13.6%)
Sex, n (%)
  Female 33 (50.8%) 19 (44.2%) 14 (63.6%) 0.19
  Male 32 (49.2%) 24 (55.8%) 8 (36.4%)
Prior therapy, n (%)
  Travoprost 43 (66.2%) 43 (100%) 0  
  Bimatoprost 18 (27.7%) 0 18 (81.8%)  
  Latanoprost 4 (6.2%) 0 4 (18.2%)  
Note: *White vs mixed-race + black.
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Figure 1 Mean IOP across visits by patient cohort.
Notes: 57 Patients attended the week 12 visit (37 from the prior travoprost cohort and 20 from the prior nontravoprost cohort). Data from the other seven patients 
were carried forward from week 4 to week 12. Error bars are shown unidirectional for clarity. *P = 0.0001, baseline versus week 4 or week 12, as measured by ANOVA. 
**P < 0.0001, baseline versus week 4 or week 12, as measured by ANOVA.
The percentage of patients from the ITT population who 
reached target IOP (#18 mmHg) was 67.2% (43 of 64) at 
week 4 and 65.6% (42 of 64) at week 12 (Figure 2). Over 
three-quarters (76.2%; 32 of 42) of patients in the prior tra-
voprost cohort reached target IOP at week 12, and nearly half 
(45.5%; 10 of 22) did so in the prior nontravoprost cohort.
In the total ITT patient population, 76.6% (49 of 64) 
achieved at least a 2-mmHg reduction in IOP from baseline at 
the week 4 visit, and 73.4% (47 of 64) did so at the week 12 
visit (Figure 3). Both prior therapy cohorts achieved similar 
proportions of $2 mmHg reductions at the week 4 visit. After 
12 weeks of treatment, 78.6% of patients in the prior travoprost 
cohort (33 of 42) and 63.6% of patients in the prior non-
travoprost cohort (14 of 22) reached $2 mmHg reductions.
Adverse events and other safety 
measures
Patients from the ITT population experienced a total of eight 
AEs, all of which were mild in severity (Table 2). All AEs, 
except the cold, were related to study medication. One patient 
who experienced ocular redness and burning discontinued 
the study as a result of the AE. No serious AEs were reported 
during the study.
Among the ITT population, 95.3% of patients at week 12 
(61 of 64 with last observation carried forward) had a CDVA 
in the study eye that was equal to or better than baseline 
CDVA. One patient had a CDVA in the study eye of 20/30 at 
the screening/baseline visit and 20/63 at week 4. This reduc-
tion was not reported as an AE, and the patient   discontinued 
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Figure 2 Percentage of patients reaching target IOP across visits by patient cohort.
Notes: 57 Patients attended the week 12 visit (37 from the previous travoprost cohort and 20 from the previous nontravoprost cohort). Data from the other seven patients 
were carried forward from week 4 to week 12.
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were carried forward from week 4 to week 12.
Table 2 Adverse events of all enrolled patients (N = 65)
Adverse event* n (%)
Redness and burning 2 (3.1)
Redness 1 (1.5)
Allergic reaction with redness, foreign body sensation, 
and burning
1 (1.5)
Blepharitis: crusting around eyes 1 (1.5)
Blepharitis: crusting around eyelash 1 (1.5)
Ocular stinging and itching 1 (1.5)
Cold 1 (1.5)
Note: *Adverse events in terminology reported by the sites.
the study by the week 12 visit due to lack of response to 
treatment. The distribution of CDVA among patients at 
week 12 was similar to the distribution at baseline. Slit-lamp 
biomicroscopy findings at week 12 showed no increases in 
the number of any ocular abnormality from baseline.
Ocular symptom survey
Of the ten symptoms queried among the ITT population, 
eight showed a decrease in the incidence scores from the 
screening/baseline visit to the week 12 visit. The other two 
demonstrated numerically higher percentages at the week 
12 visit compared with baseline (dry eye symptoms [21.1% 
versus 20.0%] and ocular stinging/burning [40.4% versus 
24.6%]; Table 3). More patients considered TTFC easy to 
administer after 12 weeks of therapy (98.2%; 56 of 57), com-
pared to the ease of administration of their baseline therapy 
(90.8%; 59 of 65).
global preference survey
After transitioning to 12 weeks of treatment with TTFC 
from prior PGA monotherapy, 84.2% of patients in the ITT 
population (48 of 57) preferred TTFC compared with 8.8% 
(5 of 57) who preferred prior therapy and 7.0% (4 of 57) 
who judged TTFC to be similar to prior therapy (Figure 4). 
Significantly more patients preferred TTFC compared with 
those who preferred previous therapy plus those who judged 
TTFC to be similar to previous therapy (P , 0.0001). Twelve 
weeks after patients had transitioned to TTFC from prior 
therapy, investigators (n = 4) preferred TTFC for 94.7% of 
their patients (54 of 57) and preferred prior therapy for 5.3% 
of their patients (3 of 57; P , 0.0001).
Discussion
The current study demonstrated that TTFC dosed in the 
evening produced a significant, additional reduction in IOP 
in patients transitioning from PGA monotherapy, whether 
examining the travoprost or nontravoprost cohort. Nearly 
two-thirds of enrolled patients reached target IOP and nearly 
three-quarters achieved at least an additional 2 mmHg 
  reduction in IOP after 12 weeks of TTFC therapy, when com-
pared to prior therapy. These findings indicate that TTFC can 
further reduce IOP in patients whose IOP failed to achieve 
sufficient reduction while on PGA monotherapy. Although 
more patients on prior travoprost therapy appeared to achieve 
IOP control than those on prior nontravoprost therapy 
(Figure 2), the small and unbalanced sizes of the cohorts 
(n = 22; nontravoprost cohort; n = 42, travoprost cohort) 
makes it difficult to draw any conclusions from the results of 
this exploratory outcome measure. A larger, controlled trial 
would have to be conducted to address this issue.
Previously published studies support the claim that TTFC 
can provide IOP improvements in patients receiving insuf-
ficient benefit from ocular hypotensive therapy. Similar to 
the current trial design, one study transitioned patients from 
monotherapy (with a PGA or a beta-blocker) to TTFC.15 
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Table 3 Survey results, with ocular symptoms at week 12 sorted from lowest to highest incidence
Baseline, n = 65 
n (%)
Week 12, n = 57  
n (%)
Presence of ocular symptoms
  Pain in or around the eye when exposed to light 5 (7.7%) 0
  Eyes more watery than usual 13 (20.0%) 2 (3.5%)
  Crusts around the eyes 5 (7.7%) 3 (5.3%)
  Irritation in eyes 20 (30.8%) 4 (7.0%)
  Foreign body sensation in the eyes after instillation 15 (23.1%) 5 (8.8%)
  Dry eye symptoms 13 (20.0%) 12 (21.1%)
  Others have said eyes looked red 21 (32.3%) 16 (28.1%)
  Redness in eyes 27 (41.5%) 17 (29.8%)
  Itchiness in or around eyes or eyelids 22 (33.8%) 18 (31.6%)
  Stinging or burning sensation after instillation 16 (24.6%) 23 (40.4%)
Ease of instillation
  Easy 59 (90.8%) 56 (98.2%)
  Moderate 6 (9.2%) 1 (1.8%)
  Difficult 0 0
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Figure 4 global preference survey.
Note: *P < 0.0001, preference for TTFC vs preference for or similar to previous therapy, both for patients and investigators.
After 6 months of   TTFC therapy, patients demonstrated a 20% 
reduction in IOP. In another study, patients were transitioned 
from monotherapy or combination therapy to TTFC; those on 
prior monotherapy achieved a 27% reduction in IOP and those 
on combination therapy demonstrated a 21% reduction after 
3 months.14 Finally, additional studies examining the transition 
of patients from either unfixed or fixed combination therapy 
with a nontravoprost PGA and a beta-blocker found that even 
these patients can benefit from transition to TTFC.16,17
As with any clinical study, this trial did have some limita-
tions that need to be considered when interpreting its results. 
The transition trial design is less controlled than a randomized 
study, which produces more robust results; however, random-
ized trial results are often less applicable to the real-world 
use of a medication. Furthermore, the trial design may have 
allowed for an imbalance in compliance between the two 
regimens being evaluated. Oftentimes, patients are more 
compliant with medications within clinical studies than in 
the “real world”.18 Because the prior PGA monotherapy was 
used outside the context of the clinical trial (ie, before the trial 
began), the possibility exists that patients may have exhibited 
increased compliance with TTFC during the clinical study, 
which could have positively impacted the IOP results. The 
open-label design of the study, and the circumstances of 
participating in a study and interacting more often with their 
physician,19 may also have affected the patients’ perception 
of the study medication. Finally, the limited scope of the 
solicited symptom survey may have created an incomplete 
assessment of the tolerability profile.
In conclusion, this study suggests that patients receiving 
insufficient IOP reduction from PGA monotherapy view 
transition to travoprost 0.004%/timolol 0.5% fixed combina-
tion favorably and can be expected to achieve further IOP 
improvements.
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